ILLUMINATE
21 Dec 2020
ILLUMINATE
NCT03994393
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.
University of Sydney
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2018-10-23 |
Anticipated End Date | - |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | Dr Shawgi Sukumaran |
Recruitment Status | Recruiting |